Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Basal Cell × cemiplimab × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 10 Skin Neoplasms 3 Lung Neoplasms 3 Carcinoma, Renal Cell 3 Squamous Cell Carcinoma of Head and Neck 2 Glioblastoma 2 Colorectal Neoplasms 2 Carcinoma 2 Triple Negative Breast Neoplasms 1 Solid Tumor 1 Sinonasal Squamous Cell Carcinoma 1 Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck 1 Rectal Neoplasms 1 Pathologic Complete Response 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Mycosis Fungoides 1 Mouth Neoplasms 1 Metastatic Castration-resistant Prostate Cancer 1 Melanoma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell 1 Lymphoma, Large-Cell, Anaplastic 1 Laryngeal Neoplasms 1 Hemangiosarcoma 1 HPV-Related Squamous Cell Carcinoma 1 Gliosarcoma 1 Eyelid Squamous Cell Carcinoma 1 Carcinoma, Basal Cell 1

Interventions

Specimen Handling 3 Nivolumab 3 Magnetic Resonance Spectroscopy 2 Ipilimumab 2 CTLA-4 Antigen 2 Biopsy 2 talimogene laherparepvec 1 prednylidene 1 deltacortene 1 daromun 1 cemiplimab 1 Vitamin D 1 Sunscreening Agents 1 Standard of Care 1 Sirolimus 1 Prednisone 1 Photochemotherapy 1 Niacinamide 1 Mohs Surgery 1 MAPRE1 protein, human 1 Curettage 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06981325 2026-03-11

CEMI-first

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Recruiting

Carcinoma, Basal Cell, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡